WS #14241
Argenx shares rose after Vyvgart hit key trial endpoints for autoimmune myositis, a large successful trial for its blockbuster drug.
Argenx positive trial results
Argenx shares rose after Vyvgart hit key trial endpoints for autoimmune myositis, a large successful trial for its blockbuster drug.